Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Drugs in R&D|August 6, 2004
Solifenacin demonstrates high absolute bioavailability in healthy menMirjam E Kuipers, Walter J J Krauwinkel, Hans Mulder, et al.
Clinical Drug Investigation|September 1, 2011
Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjectsStephan A Veltkamp, Takeshi Kadokura, Walter J J Krauwinkel, et al.
Basic & Clinical Pharmacology & Toxicology|July 27, 2006
Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteersPieter J Swart, Walter J J Krauwinkel, Ronald A Smulders, et al.
European Journal of Clinical Pharmacology|April 11, 2008
The effect of paroxetine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjectsTakeshi Kadokura, Martin den Adel, Walter J J Krauwinkel, et al.
European Journal of Clinical Pharmacology|April 29, 2008
The effect of fluvoxamine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjectsTakeshi Kadokura, Martin den Adel, Walter J J Krauwinkel, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Evaluation of the Pharmacokinetic Interaction Between the β3 -Adrenoceptor Agonist Mirabegron and the Muscarinic Receptor Antagonist Solifenacin In Healthy SubjectsWalter J J Krauwinkel, Virginie M M Kerbusch, John Meijer, et al.
Clinical Therapeutics|November 18, 2005
Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled studyMiriam E J Taekema-Roelvink, Piet J Swart, Mirjam E Kuipers, et al.
Clinical Drug Investigation|June 5, 2013
The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitorWenhui Zhang, Walter J J Krauwinkel, James Keirns, et al.
Pageof 1